Trinity Biotech exhibits cardiac diagnostics point-of-care system at MEDICA

20 November 2013

Trinity Biotech is displaying its new 15-minute-analysis Meritas Troponin I (TnI) point-of-care test at MEDICA this week. This landmark Troponin I test is a high sensitivity, ACC, ESC and AHA guideline-compliant Troponin assay.

Designed for use with the revolutionary Meritas POC Analyzer, the Meritas Troponin I test enables fast, accurate triage and intervention for patients presenting at the emergency department with a possible myocardial infarction (MI), as well as for risk stratification of patients. Results, which are traceable to NIST SRM 2921, are comparable to those obtained using traditional top performing laboratory analyzers, and are available in just 15 minutes.

 The company says turnaround times, patient care and outcomes are improved, helping to maximize the use of precious hospital resources and generate significant cost savings. Studies are currently underway to validate the clinical performance of the Meritas Troponin I POC test to obtain CEĀ­ marking, and additional assays are being developed to extend the test menu further.


To top